Merck, Samsung rack up data on Humira biosim, setting stage for approval apps

Industry watchers expect biosimilars for AbbVie's ($ABBV) Humira to be the most successful copycat biologics launched in the U.S. and Europe, and that's something Merck ($MRK) and Samsung are trying to get in on. Now, the biosim partners are one step closer, with their knockoff clearing late-stage trials and setting the stage for global regulatory applications. Report | More

Suggested Articles

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.